HTA Alignment & Gene Therapy Value

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are particularly timely given the current policy shifts.

MarcusSame here. We're looking at CMS Part D Redesign Operational Hurdles — why the implementation is creating more questions than answers for sponsors. Then ICER's new Alzheimer's Evidence Report with New Endpoints — what that means for value frameworks. And EMA's Rare Disease Adaptive Pathway Expansion — the implications for HTA alignment. Finally, FDA's Breakthrough Therapy Designation Update for Gene Therapies — how it's changing the development pathway.

SaraThat first one on CMS Part D is interesting to me — the operational hurdles are one thing, but the budget impact for payers is going to be significant and not yet quantified.

MarcusExactly. Let's get into it.

MarcusStarting with CMS Part D Redesign. The implementation is facing operational hurdles that are creating uncertainty for sponsors. The new model includes enhanced rebates and changes to the benefit structure, but the operational complexity is substantial. Sponsors are reporting challenges with data submission and integration.

SaraThat's one read — I'd frame it slightly differently. The operational hurdles are real, but what strikes me is the lack of clarity on how the new rebate structures will affect net prices. Payers are concerned about the pass-through costs and the potential for increased premiums.

MarcusThat's fair, and I think payers would see it that way. But from the sponsor side, the data integration challenges are the immediate pain point. The requirement for real-time data submission is something many weren't prepared for.

SaraI wonder if that's the full picture though. The data challenges are significant, but the real issue is the timing. The implementation timeline is aggressive, and sponsors are struggling to meet the deadlines without compromising data quality.

MarcusThat connects to something I keep coming back to: the tension between speed and accuracy. CMS is pushing for rapid implementation, but the data infrastructure isn't there yet. This could lead to incomplete data being submitted, which would affect both pricing and coverage decisions.

SaraRight, and from the payer side, we're worried about the downstream impact on formulary management. If the data is incomplete, how can we make informed decisions about coverage and reimbursement?

MarcusMoving to ICER. Their new Alzheimer's Evidence Report is incorporating novel endpoints, including cognitive and functional measures that go beyond traditional ADAS-Cog. This is a significant shift in how value is being assessed for these therapies.

SaraThat's interesting. The inclusion of new endpoints is a step forward, but I have concerns about the reliability of these measures. ICER is taking a risk by giving them equal weight in their cost-effectiveness models.

MarcusThat's one read — I'd frame it slightly differently. The new endpoints reflect a more holistic view of patient outcomes, which is necessary given the progressive nature of Alzheimer's. But the methodological challenges are substantial, especially in terms of validating these endpoints in real-world settings.

SaraThe part that gives me pause is the budget impact. Even if these endpoints are valid, the cost of these therapies is so high that any incremental benefit, no matter how measured, will face scrutiny on value for money.

MarcusI wonder if that's the full picture though. The inclusion of new endpoints might actually help in justifying higher prices if they demonstrate meaningful benefits. But it's a double-edged sword because the uncertainty around the endpoints could lead to lower value scores.

SaraRight, and from the payer side, we're seeing a shift towards outcomes-based contracts. ICER's new framework might influence how these contracts are structured, but it's still early days.

MarcusNext, EMA's Rare Disease Adaptive Pathway Expansion. The agency is expanding the eligibility criteria for the adaptive pathway to include more rare diseases, aiming to accelerate development and access. This is a significant move to address the unmet needs in rare disease populations.

SaraThat's fair, though I think payers would see it differently. While the expansion is welcome, the concern is that it might lead to more conditional approvals based on limited data, which could increase uncertainty for reimbursement decisions.

MarcusThat's a valid point. The adaptive pathway is designed to be flexible, but the trade-off is that the evidence at approval might be less robust. For rare diseases, this is often necessary, but it creates challenges for HTA bodies that require robust data for cost-effectiveness assessments.

SaraI'd push back slightly on that. The adaptive pathway includes post-marketing requirements, so the evidence can be strengthened over time. But the key is whether HTA bodies will be willing to reassess based on that follow-up data.

MarcusExactly. And what's striking here is the potential for divergence between regulatory and HTA decisions. A drug might get approved via the adaptive pathway but face delays in HTA due to insufficient initial evidence.

SaraThis connects to something I keep coming back to: the need for better alignment between regulatory and HTA processes. The expansion of the adaptive pathway could be an opportunity to test new models of collaboration.

MarcusFinally, FDA's Breakthrough Therapy Designation Update for Gene Therapies. The agency has updated the criteria to include more gene therapies, particularly in areas with high unmet need. This is a significant update that could accelerate the development of these complex products.

SaraThat's interesting. The expansion of Breakthrough Therapy Designation is a positive step, but I'm concerned about the implications for evidence generation. Gene therapies are often one-time treatments with high upfront costs, so the evidence needs to be particularly robust to justify the price.

MarcusThat's one read — I'd frame it slightly differently. The update reflects the recognition that gene therapies require a different approach to evidence generation. The FDA is signaling that they are more willing to consider surrogate endpoints and real-world evidence for these products.

SaraThe part that gives me pause is the potential for accelerated approvals based on limited data. While it might get therapies to patients faster, it could lead to post-marketing surprises that affect long-term value.

MarcusI wonder if that's the full picture though. The FDA is also emphasizing the importance of post-marketing studies, so there's a balance. But the challenge for sponsors is how to design these studies to provide meaningful data without delaying access.

SaraRight, and from the payer side, we're worried about the budget impact. If multiple gene therapies get breakthrough designation and accelerated approval, the cumulative cost could be substantial.

SaraA lot to think about today. I'll be watching how CMS addresses the operational hurdles in Part D and whether it leads to any policy adjustments.

MarcusSame — and for me the thread running through today is the tension between speed and rigor across regulatory and HTA processes. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.